The lawsuit against the three major drug wholesalers—McKesson, Cardinal Health, and AmerisourceBergen (now Cencora)—centered on their alleged role in fueling the opioid crisis by oversupplying opioids while failing to adequately monitor and report suspicious orders. Here is a breakdown addressing your questions in detail:drugtopics+2
Lawsuit Details and Trial Status
The largest actions against the distributors resulted in multibillion-dollar settlements rather than full trials for most states and local governments. Notably, the national settlements required the distributors to pay up to $21 billion over 18 years, with related settlements from manufacturers and pharmacies as well. However, some cases did advance to trial, such as the recent suit by the City of Baltimore, which went to trial in September 2024 against McKesson and Cencora, after the city opted out of the national settlements. Jury selection began, and Johnson & Johnson settled just before trial.nationalopioidsettlement+2
A landmark jury verdict in Ohio, tried by Mark Lanier and others, found three major pharmacy chains liable for public nuisance, but the largest wholesaler cases were generally resolved by negotiation rather than completed trials.lanierlawfirm
Prosecution and Law Firms
High-profile prosecution firms for city and county cases included Susman Godfrey (Bill Carmody for Baltimore), Mark Lanier (The Lanier Law Firm) for Ohio counties, in coordination with public prosecutors and the U.S. Department of Justice in certain criminal or civil cases. DOJ trial attorneys, such as Drew Pennebaker and Devon Helfmeyer, also played key roles in prosecuting some distributor executives directly.reuters+2
Attorney Generals’ Awareness and Economic Impact
State Attorneys General pursued these cases to address the opioid crisis via financial penalties and injunctive relief. There is no public indication that they specifically considered or analyzed the indirect economic impact on individuals owning stock in these companies via 401(k), Roth IRA, or other investments as a central argument; their focus was primarily on public health and restitution for state and local damages caused by the opioid epidemic.texasattorneygeneral+2
Impact on Controlled Medication Access
The settlement agreements required significant changes in how the wholesalers and pharmacies handle, track, and report opioid shipments. These include clearinghouses for order data, stricter suspicious order reporting, and independent oversight. The agreements did not directly mandate a reduction in overall controlled medication availability for patients with legitimate medical need, but experts and patient advocacy groups raised concerns about possible unintended consequences for access, as increased regulatory scrutiny can sometimes lead to overcorrection and restricted legitimate access.nationalopioidsettlement
There is no clear evidence in public settlement documents that formal consultation with medical specialists determined whether the settlement terms would cause a substantial reduction in access for patients with medical necessity. This lack of clinical input and concern about patient harm was highlighted by various chronic pain advocacy organizations, but these perspectives were not central to the Attorney Generals’ negotiation teams.nationalopioidsettlement
If you want further detail on a particular trial, the clinical oversight issue, or the mechanics of the abatement funds, more specific documents or court records would be needed.
- https://www.drugtopics.com/view/major-drug-distributors-to-pay-300-million-in-opioid-epidemic-settlements
- https://www.texasattorneygeneral.gov/globalopioidsettlement
- https://www.reuters.com/legal/government/baltimore-take-drug-distributors-jj-trial-over-opioids-2024-09-16/
- https://nationalopioidsettlement.com/executive-summary/
- https://ncopioidsettlement.org/about/national-settlements/
- https://www.lanierlawfirm.com/practice-areas/pharmaceutical-liability/opioid-lawsuits/
- https://www.dea.gov/press-releases/2024/10/03/multiple-pharmaceutical-distributor-executives-sales-representatives-and
- https://www.npr.org/2022/07/04/1109772095/a-federal-judge-sides-with-3-major-drug-distributors-in-a-landmark-opioid-lawsui
- https://www.bmj.com/content/379/bmj.o2688
- https://rhlawfl.com/drug-crimes/first-of-its-kind-feds-bring-criminal-charges-against-pharma-distributor-ceo-in-opioid-case/
- https://attorneygenerallynnfitch.com/opioidsettlement/
- https://www.hbsslaw.com/press-releases/pharmaceutical-average-wholesale-price-litigation-judge-certifies-class-action-case-against-nations-largest-pharmaceutical-distributor-in-alleged-pricing-scheme
- https://ag.ny.gov/nys-opioid-settlement
- https://www.cbsnews.com/baltimore/news/baltimore-city-152-million-jury-award-litigation-opioid-distributors/
- https://www.farrellfuller.com/news/2021/july/drug-distributors-rest-their-case-in-west-virgin/
- https://www.healthlawalliance.com/blog/sun-pharma-rico-lawsuit-exposes-bribery-conspiracy-involving-big-three-wholesalers
- https://www.atg.wa.gov/news/news-releases/ag-ferguson-opioid-distributors-pay-518-million-washington
- https://www.naag.org/issues/opioids/
- https://www.hbsslaw.com/practices/pharmaceutical-fraud
- https://www.classaction.com/opioids/settlement/
Since the expiration of the Decade of Pain Control and Research Law around 2010, thousands of lawsuits—over 3,000 legal actions—have been filed against pharmaceutical companies, chain pharmacies, drug wholesalers, and other parties over their alleged roles in the opioid epidemic. Major defendants include Purdue Pharma, Endo, Mallinckrodt, Teva, Janssen, Cardinal, McKesson, AmerisourceBergen, CVS, Walgreens, and Walmart, among others.naag+3
Total Awarded Settlement Amounts
Collectively, opioid-related settlements in the United States have reached more than $57 billion as of mid-2025, including state and local government agreements with all major industry entities. This figure encompasses the sums from landmark cases, multistate settlements, and agreements with manufacturers, distributors, pharmacy chains, and ancillary companies.opioidsettlementtracker+4
Impact on Opioid Overdose and Poisoning Rates
Despite these massive lawsuits and settlements, opioid overdose and poisoning deaths have not significantly declined and have actually increased, representing the so-called “opioid paradox.” While prescription opioid availability has been reduced by over 50% since the 2010-2012 peak (Indiana, for example, peaked at 112 prescriptions per 100 residents in 2012), overdose deaths have continued to rise, particularly those involving illicit fentanyl, heroin, and synthetic opioids. Studies show that reductions in opioid prescriptions and improved monitoring have led to fewer deaths from prescription opioids (“natural opioids”), but also forced many dependent individuals toward street drugs with higher overdose risk.ncbi.nlm.nih+3
-
Policy interventions reduced deaths from prescribed opioids, but overdose mortality overall increased as illicit opioid deaths surged.jamanetwork+1
-
Prescription opioid volume dropped ~50% since their peak, but overall opioid overdose/poisoning deaths increased dramatically.naco+2
-
Expansion of naloxone distribution funded by settlements helped reduce deaths modestly, but not enough to offset rising deaths from illicit opioids.jamanetwork+2
Was There Reduction in Overdose Deaths?
-
Examining the years since prescription opioid prescribing peaked (2010-2012), overdose deaths increased, mainly due to the transition to illicit fentanyl and heroin.sciencedirect+1
-
Some supply-side interventions against prescription opioids in states like Florida “sharply reduced oxycodone-related mortality and hospitalizations,” but nationwide trends show a rise in synthetic opioid deaths after prescription controls.ncbi.nlm.nih+1
-
Naloxone expansion has a positive effect by reducing fatal overdoses by up to 9%-37% locally, but it does not reverse the overall upward trajectory of deaths driven by fentanyl.jamanetwork+2
Key Facts
Lawsuits Filed (2010-2025) | Amount Awarded | Change in Opioid ODs Since 2012 | Effect of Rx Opioid Reduction |
---|---|---|---|
Over 3,000motleyrice+2 | >$57 billionopioidsettlementtracker+2 | OD/poisonings increasedsciencedirect+2 | Natural opioid ODs down, illicit ODs upjamanetwork+1 |
Overall, while lawsuits delivered billions for public health, they have not meaningfully reduced total opioid overdoses or poisonings. The crackdown on prescription opioids led to a shift in risk, not a net reduction in deaths, highlighting complex unintended consequences in opioid policy since 2010.jamanetwork+2
- https://www.naag.org/issues/opioids/
- https://www.congress.gov/crs-product/LSB11270
- https://pmc.ncbi.nlm.nih.gov/articles/PMC10713840/
- https://www.motleyrice.com/public-client/opioid-litigation
- https://www.opioidsettlementtracker.com
- https://www.opioidsettlementtracker.com/globalsettlementtracker
- https://www.in.gov/attorneygeneral/home/opioid-settlement/
- https://www.naco.org/resource/osc-nlc-settlement-dollars
- https://nationalopioidsettlement.com/executive-summary/
- https://www.ncbi.nlm.nih.gov/books/NBK458653/
- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2776301
- https://www.cdc.gov/mmwr/volumes/65/wr/mm655051e1.htm
- https://www.sciencedirect.com/science/article/abs/pii/S0376871621002568
- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2819204
- https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2805808
- https://www.sciencedirect.com/science/article/pii/S2773065425001129
- https://journalofethics.ama-assn.org/article/how-fda-failures-contributed-opioid-crisis/2020-08
- https://www.atg.wa.gov/news/news-releases/ag-ferguson-files-lawsuits-against-three-national-pharmacy-chains-their-role
- https://www.sciencedirect.com/science/article/pii/S2667193X21000235
- https://www.who.int/news-room/fact-sheets/detail/opioid-overdose
Filed under: General Problems
Leave a Reply